Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy

Estimation of Tissue Level of Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy: a Case-control Study.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03483311

Enrollment

Registered

2018-03-30

Start date

2018-03-01

Completion date

2018-09-30

Last updated

2018-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

• Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.

Interventions

OTHERskin biopsy before and after NB-UVB phototherapy

skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with psoriasis (adults and children above 12years) * Both sexes. * New cases or cases not receiving any treatment for at least 3 months ago.

Exclusion criteria

* Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...) * Erythrodermic and pustular psoriasis. * History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Design outcomes

Primary

Measure	Time frame
Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.	6 months

Countries

Egypt

Contacts

Primary ContactMaha Fathy Elmasry, MD

mahafathy1214@gmail.com01222633740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026